Literature DB >> 17288549

Molecular basis of cerebral neurodegeneration in prion diseases.

Jörg Tatzelt1, Hermann M Schätzl.   

Abstract

The biochemical nature and the replication of infectious prions have been intensively studied in recent years. Much less is known about the cellular events underlying neuronal dysfunction and cell death. As the cellular function of the normal cellular isoform of prion protein is not exactly known, the impact of gain of toxic function or loss of function, or a combination of both, in prion pathology is still controversial. There is increasing evidence that the normal cellular isoform of the prion protein is a key mediator in prion pathology. Transgenic models were instrumental in dissecting propagation of prions, disease-associated isoforms of prion protein and amyloid production, and induction of neurodegeneration. Four experimental avenues will be discussed here which address scenarios of inappropriate trafficking, folding, or targeting of the prion protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17288549     DOI: 10.1111/j.1742-4658.2007.05633.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  15 in total

1.  Proteolysis of prion protein by cathepsin S generates a soluble beta-structured intermediate oligomeric form, with potential implications for neurotoxic mechanisms.

Authors:  Oxana Polyakova; Denise Dear; Igor Stern; Stephen Martin; Elizabeth Hirst; Suleman Bawumia; Angus Nash; Guy Dodson; Igor Bronstein; Peter M Bayley
Journal:  Eur Biophys J       Date:  2008-09-24       Impact factor: 1.733

2.  Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein.

Authors:  Max Nunziante; Kerstin Ackermann; Kim Dietrich; Hanna Wolf; Lars Gädtke; Sabine Gilch; Ina Vorberg; Martin Groschup; Hermann M Schätzl
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

3.  Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.

Authors:  Pelagia Deriziotis; Ralph André; David M Smith; Rob Goold; Kerri J Kinghorn; Mark Kristiansen; James A Nathan; Rina Rosenzweig; Dasha Krutauz; Michael H Glickman; John Collinge; Alfred L Goldberg; Sarah J Tabrizi
Journal:  EMBO J       Date:  2011-07-08       Impact factor: 11.598

4.  Effect of PrP105-132 on the secretion of interleukin-6 and interleukin-8 from microglial cells in vitro.

Authors:  Yun-Tian Yang; Shan Jin
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

5.  Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues.

Authors:  Shugui Chen; Satya P Yadav; Witold K Surewicz
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

6.  Infectious prion protein alters manganese transport and neurotoxicity in a cell culture model of prion disease.

Authors:  Dustin P Martin; Vellareddy Anantharam; Huajun Jin; Travis Witte; Robert Houk; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2011-08-19       Impact factor: 4.294

Review 7.  The ubiquitin-proteasome system in spongiform degenerative disorders.

Authors:  Brandi R Whatley; Lian Li; Lih-Shen Chin
Journal:  Biochim Biophys Acta       Date:  2008-08-23

Review 8.  Prion diseases: from protein to cell pathology.

Authors:  Gabor G Kovacs; Herbert Budka
Journal:  Am J Pathol       Date:  2008-02-02       Impact factor: 4.307

9.  Introducing a rigid loop structure from deer into mouse prion protein increases its propensity for misfolding in vitro.

Authors:  Leah M Kyle; Theodore R John; Hermann M Schätzl; Randolph V Lewis
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis.

Authors:  Ajay Singh; Maradumane L Mohan; Alfred Orina Isaac; Xiu Luo; Jiri Petrak; Daniel Vyoral; Neena Singh
Journal:  PLoS One       Date:  2009-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.